X
[{"orgOrder":0,"company":"Tiumbio","sponsor":"Oncodesign","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Hansoh Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TiumBio and Hansoh Pharma Announce Clinical Trial Approval of 'HS-10518\/TU2670' from NMPA in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Tiumbio","sponsor":"SK Chemicals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TiumBio Secures KRW 38.5 Billion in Anticipation of Upcoming Clinical Data","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TiumBio Submits CTA for Phase 1b Clinical Trial of TU7710, a Long-acting Recombinant Activated Factor VII, in Hemophilia A or B Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TiumBio Announces Positive Topline Data from Phase 2a Trial of Merigolix in Patients with Moderate to Severe Endometriosis-associated Pain","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Tiumbio
Filters
Companies By Therapeutic Area
Details:
TU2670 (merigolix) is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, which is being investigated in females with endometriosis-associated-pain.
Lead Product(s):
Merigolix
Therapeutic Area: Obstetrics/Gynecology (Women’s Health)
Product Name: TU2670
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 08, 2024
Details:
TU7710, a novel recombinant activated factor VII (rFVIIa) for hemophilia patients with inhibitors. It is being evaluated in the Phase I clinical trial studies for the treatment of Hemophilia A & B and also Blood Coagulation Disorders.
Lead Product(s):
TU7710
Therapeutic Area: Genetic Disease
Product Name: TU7710
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 26, 2024
Details:
The proceeds will be primarily allocated to support TiumBio's clinical programs that include a Phase 2 trial of TU2670 (merigolix), a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in endometriosis.
Lead Product(s):
Merigolix
Therapeutic Area: Obstetrics/Gynecology (Women’s Health)
Product Name: TU2670
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
SK Chemicals
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Private Placement
December 29, 2023
Details:
TU2670 is an orally active non-peptide GnRH antagonist currently undergoing a Phase 2a clinical study in the EU for the treatment of moderate to severe pain associated with endometriosis.
Lead Product(s):
HS-10518
Therapeutic Area: Neurology
Product Name: TU2670
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Hansoh Pharma
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 05, 2023
Details:
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.
Lead Product(s):
Nanocyclix Drug Candidates
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Oncodesign
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
October 21, 2021